Opens in a new tab

Pfizer v GlaxoSmithKline Biologicals (CFI, 3 December 2024)

Date3 December 2024
CourtCFI
DivisionMilan (IT) Central Division- Section
Type of actionPreliminary objection
Registry referenceApp_56246/2024 · ORD_58802/2024
PartiesPfizer Manufacturing Belgium S.A, Pfizer Inc, Pfizer Europe MA EEIG, Pfizer S.A, Pfizer Ltd, Pfizer Pharma GmbH, Pfizer Service Company S.R…

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 2 December 2024 (UPC_CFI_476/2024, ACT_45928/2024, ORD_58802/2024), the Milan Central Division dismissed GlaxoSmithKline Biologicals’ preliminary objection to Pfizer’s revocation action against EP 4 183 412. The order clarifies two conditions of Art. 33(4) UPCA: identity of parties is assessed entity by entity, and the earlier infringement action must concern a patent already granted.

Question

Does an infringement action brought before the Düsseldorf Local Division before the mention of grant deprive the Central Division of competence over the revocation action, where two of the claimants are not defendants there?

Decision

« The same parties » requires identity of parties, each legal entity being considered individually. Membership of the same group is not enough, and the overlap here is only partial. Moreover, a patent is granted on the date the mention of grant is published in the European Patent Bulletin (14 August 2024), the Düsseldorf action, lodged on 5 August 2024, therefore appears inadmissible when brought and cannot defeat the Central Division’s competence. The objection does not stay the proceedings (Rule 19.6), no hearing was needed and the auxiliary request for a stay was refused. Leave to appeal was granted.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts. 2(e) to (g), 32(1)(a), 33(4) and 73(2)(b)
Rules of Procedure
Rules 19, 220.2, 264, 271.6(b) and 295(m)
European Patent Convention
Art. 64(1), Art. 97(3)
Regulation (EU) No 1257/2012
Art. 4(1)
Case law cited
Edwards Lifesciences v Meril Italy, Paris Central Division, 13 November 2023, Amgen v Sanofi-Aventis Deutschland, Munich Central Division, 24 August 2023, Seoul Viosys v Laser Components, Paris Local Division, 24 July 2024, Tesla v Avago, Munich Local Division, 25 August 2023

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Local and central divisions (UPC).

Dhenne Avocats blog: The Transitional Period and the UPC: Coordinating Two Judicial Orders.

Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction, Valeo v. Bosch and the Redistribution of Cases Within the UPC (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Preliminary objection
Outcome (Dhenne Avocats summary)
L'exception préliminaire est rejetée : l'identité de parties de l'art. 33, paragraphe 4, s'apprécie entité par entité, et une action en contrefaçon introduite avant la mention de la délivrance ne fait pas obstacle à la compétence de la division centrale.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 183 412Mentioned in the analysis (role not qualified)
Also mentioned in 4 other decision(s): Pfizer v GlaxoSmithKline Biologicals (CFI, ORD_18700/2025, 22 April 20 · Pfizer v GlaxoSmithKline Biologicals (CFI, ORD_18810/2025, 22 April 20 · GlaxoSmithKline Biologicals v Pfizer Europe MA EEIG (CFI, 11 April 202 · GlaxoSmithKline Biologicals v Pfizer Europe MA EEIG (CFI, 4 March 2025
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.